MOUNTAIN VIEW, Calif., March 8 /PRNewswire-FirstCall/ -- Aerogen, Inc. , a specialty pharmaceutical company, will hold its quarterly investor conference call to discuss fourth quarter results on Wednesday, March 9, at 5:00 p.m. Eastern Time (2 p.m. Pacific Time).
This call is being webcast by Thomson/CCBN and can be accessed at Aerogen's Web site at http://www.aerogen.com/.
The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at http://www.fulldisclosure.com/, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (http://www.streetevents.com/).
Aerogen, a specialty pharmaceutical company, develops products based on its OnQ(R) Aerosol Generator technology to improve the treatment of respiratory disorders in the acute care setting. Aerogen has presented the results of its first Phase 2 clinical study evaluating delivery of aerosolized amikacin for the treatment of ventilator-associated pneumonia; an additional Phase 2 study is currently underway. Following amikacin, additional drug products targeting improved respiratory therapy in the acute care setting are in the feasibility and pre-clinical stages of development. Aerogen's Aeroneb(R) Professional Nebulizer System is marketed world-wide for use in hospitals. Aerogen's Aeroneb(R) Go Nebulizer for home use is currently marketed in the U.S., Japan and certain European countries. Aerogen also has development collaborations with pharmaceutical and biotechnology companies for use of its technology in the delivery of novel compounds that treat respiratory and other disorders. Aerogen is headquartered in Mountain View, California, with a campus in Galway, Ireland. For more information, visit http://www.aerogen.com/.
CONTACT: Jane E. Shaw, Ph.D. of Aerogen, Inc., +1-650-864-7333, firstname.lastname@example.org